Harnessing mesenchymal stem cell homing as an anticancer therapy
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Mesenchymal stromal cells (MSCs) are non-hematopoietic progenitor cells that have been exploited as vehicles for cell-based cancer therapy. The general approach is based on the innate potential of adoptively applied MSC to undergo facilitated recruitment to malignant tissue. MSC from different tissue sources have been engineered using a variety of therapy genes that have shown efficacy in solid tumor models. AREAS COVERED: In this review we will focus on the current developments of MSC-based gene therapy, in particular the diverse approaches that have been used for MSCs-targeted tumor therapy. We also discuss some outstanding issues and general prospects for their clinical application. EXPERT OPINION: The use of modified mesenchymal stem cells as therapy vehicles for the treatment of solid tumors has progressed to the first generation of clinical trials, but the general field is still in its infancy. There are many questions that need to be addressed if this very complex therapy approach is widely applied in clinical settings. More must be understood about the mechanisms underlying tumor tropism and we need to identify the optimal source of the cells used. Outstanding issues also include the therapy transgenes used, and which tumor types represent viable targets for this therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., Noël, D., & Jorgensen, C. (2003) · Blood · doi:10.1182/blood-2003-04-1193 · Cited by 1,166 · cited 1×
“Within tumors, MSCs can modulate both innate and adaptive immune processes [91].”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Honczarenko, M., Le, Y., Swierkowski, M., Ghiran, I., Glodek, A. M., & Silberstein, L. E. (2006) · Stem Cells · doi:10.1634/stemcells.2005-0319 · Cited by 722
Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model
Nakamura, K., Ito, Y., Kawano, Y., Kurozumi, K., Kobune, M., Tsuda, H., Bizen, A., Honmou, O., Niitsu, Y., & Hamada, H. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302276 · Cited by 597 · cited 2×
“successfully prolonged by treatment [131].”
BackgroundKlopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562 · cited 1×
“tumor immune response is an important consideration in the application of tumor therapy [7,10,23,95,113].”
BackgroundImmunosuppression by mesenchymal stem cells: mechanisms and clinical applications
Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C., & Noël, D. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt2 · Cited by 507
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
Wong, C. C.-L., Gilkes, D. M., Zhang, H., Chen, J., Wei, H., Chaturvedi, P., Fraley, S. I., Wong, C.-M., Khoo, U.-S., Ng, I. O.-L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113483108 · Cited by 437 · cited 3×
“MSCs can suppress T cells via their secretion of diverse factors including PGE2, indoleamine 2,3-dioxygenase, TGF-β, HGF, nitric oxide (NO), and hemoxygenase 1 [44,45,76,83,90,95,97–103].”
BackgroundAdipose Tissue–Derived Human Mesenchymal Stem Cells Mediated Prodrug Cancer Gene Therapy
Kucerova, L., Altanerova, V., Matuskova, M., Tyciakova, S., & Altaner, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4024 · Cited by 431
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417 · cited 2×
“tumor cells, while most normal tissues do not express the TRAIL receptors DR4 (TRAIL-RI) and DR5 (TRAIL-RII) [62,162].”
BackgroundMcLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45273 · Cited by 380
Research works printed but not linked: 180
- 10.1038/onc.2013.121 · DOI · Paper page
- 10.1007/s12265-011-9257-3 · DOI
- 10.1111/j.1365-2141.2007.06786.x · DOI
- 10.1080/14653240600855905 · DOI · Paper page
- 10.1111/j.1749-6632.2012.06551.x · DOI · Paper page
- 10.4252/wjsc.v2.i4.67 · DOI · Paper page
- 10.1634/stemcells.2007-1006 · DOI · Paper page
- Bagley RG, 2008, Int J Oncol, 34, 9
- 10.1016/j.bbmt.2005.01.005 · DOI · Paper page
- 10.3727/096368910X508762 · DOI · Paper page
- 10.1634/stemcells.2007-0197 · DOI · Paper page
- 10.5966/sctm.2011-0018 · DOI · Paper page
- 10.1155/2016/4285215 · DOI · Paper page
- 10.2174/1567201810999131125222440 · DOI
- 10.1089/wound.2015.0627 · DOI
- 10.1002/bdrc.20174 · DOI
- 10.1186/1755-1536-5-20 · DOI
- 10.3727/096368912X653246 · DOI
- 10.1016/j.bbcan.2013.10.004 · DOI · Paper page
- 10.1007/s10555-010-9222-7 · DOI · Paper page
- 10.1007/s11060-007-9332-4 · DOI · Paper page
- 10.1186/2045-3701-3-5 · DOI
- 10.1158/0008-5472.CAN-08-3562 · DOI · Paper page
- 10.1038/nature06188 · DOI · Paper page
- 10.1056/NEJM198612253152606 · DOI · Paper page
- 10.1016/j.ccr.2011.01.020 · DOI · Paper page
- 10.1161/CIRCRESAHA.108.176826 · DOI · Paper page
- 10.1002/stem.645 · DOI · Paper page
- Kidd S, 2012, PLoS One, 7
- 10.1089/scd.2005.14.329 · DOI · Paper page
- 10.1159/000047856 · DOI · Paper page
- 10.1016/j.mvr.2009.02.001 · DOI · Paper page
- 10.1093/jnci/djh299 · DOI · Paper page
- 10.1089/scd.2012.0060 · DOI
- 10.1002/pmic.201200179 · DOI · Paper page
- 10.1002/ijc.27735 · DOI · Paper page
- 10.1002/stem.1269 · DOI
- 10.1016/j.jcyt.2012.10.003 · DOI · Paper page
- 10.1186/scrt221 · DOI · Paper page
- 10.1371/journal.pone.0012180 · DOI · Paper page
- 10.1158/0008-5472.CAN-12-3086 · DOI · Paper page
- Choi SA, 2015, PLoS One, 10, e0129292, 10.1371/journal.pone.0129292 · DOI
- Mirzaei H, 2016, Curr Med Chem
- 10.1038/nri2156 · DOI · Paper page
- 10.1634/stemcells.2007-0054 · DOI · Paper page
- 10.1111/j.1365-2141.2007.06610.x · DOI · Paper page
- 10.1089/ars.2010.3582 · DOI · Paper page
- Wang GLAGLS, 1993, J Biol Chem, 268, 21513, 10.1016/S0021-9258(20)80571-7 · DOI · Paper page
- Chaturvedi P, 2013, J Clin Invest, 123, 189
- 10.18632/oncotarget.1040 · DOI
- Studeny M, 2002, Cancer Res, 62, 3603
- 10.1634/stemcells.2008-0084 · DOI · Paper page
- 10.1152/ajpheart.00523.2005 · DOI · Paper page
- 10.1002/stem.81 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-1406 · DOI · Paper page
- 10.1371/journal.pone.0025663 · DOI
- 10.1002/stem.1198 · DOI · Paper page
- 10.1002/jcb.21172 · DOI · Paper page
- 10.3324/haematol.10669 · DOI · Paper page
- 10.1634/stemcells.2004-0342 · DOI · Paper page
- 10.1016/j.ejca.2012.05.005 · DOI · Paper page
- 10.4049/jimmunol.1402097 · DOI · Paper page
- 10.1084/jem.20030267 · DOI · Paper page
- 10.1038/nm1075 · DOI · Paper page
- 10.1186/1479-5876-12-59 · DOI
- 10.1016/j.pharmthera.2013.10.006 · DOI · Paper page
- 10.1007/s10555-006-9036-9 · DOI · Paper page
- 10.1038/nature04186 · DOI · Paper page
- 10.1038/485S55a · DOI
- 10.1002/ijc.11542 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-1865 · DOI · Paper page
- 10.1016/j.yexcr.2010.07.002 · DOI · Paper page
- Luboshits G, 1999, Cancer Res, 59, 4681
- Niwa Y, 2001, Clin Cancer Res, 7, 285
- Hamada S, 2012, Pancreatic cancer and tumor microenvironment
- 10.1158/0008-5472.CAN-10-0538 · DOI · Paper page
- 10.1158/2159-8290.CD-12-0101 · DOI · Paper page
- 10.1186/s40164-015-0007-0 · DOI
- 10.3892/ijo.2010.869 · DOI
- 10.1016/j.imlet.2014.03.001 · DOI
- 10.1038/onc.2013.272 · DOI · Paper page
- Xu G, 2007, Cell Res, 17, 240, 10.1038/cr.2007.4 · DOI
- 10.1002/stem.1986 · DOI
- 10.1158/0008-5472.CAN-13-1656 · DOI · Paper page
- 10.1007/s12272-012-0202-z · DOI · Paper page
- 10.1002/stem.2234 · DOI
- 10.1111/sji.12102 · DOI
- 10.1007/s00441-014-1926-5 · DOI
- 10.1371/journal.pone.0027618 · DOI · Paper page
- 10.1634/stemcells.2006-0548 · DOI · Paper page
- 10.4049/jimmunol.1102996 · DOI · Paper page
- 10.1089/scd.2013.0433 · DOI
- 10.1007/s00277-011-1156-9 · DOI
- 10.1097/TP.0b013e3181a285b0 · DOI · Paper page
- 10.1038/nri2395 · DOI · Paper page
- 10.1186/s40635-015-0065-y · DOI
- 10.1182/blood-2007-02-069716 · DOI · Paper page
- 10.2174/156652307781369119 · DOI
- 10.1021/mp200151a · DOI
- 10.1016/j.addr.2011.06.010 · DOI · Paper page
- 10.1073/pnas.0806647106 · DOI · Paper page
- 10.1517/14712598.8.1.17 · DOI
- 10.4155/tde.11.141 · DOI
- 10.1016/j.ejca.2014.06.014 · DOI
- 10.1186/s12916-015-0426-0 · DOI
- Jiang J, 2014, Oncol Rep, 31, 781, 10.3892/or.2013.2898 · DOI
- 10.1089/ars.2014.6183 · DOI
- 10.1227/01.NEU.0000345646.85472.EA · DOI
- 10.1111/j.1600-0625.2006.00479.x · DOI · Paper page
- 10.1016/j.canlet.2009.08.031 · DOI · Paper page
- Wang A, 2015, Int J Clin Exp Med, 8, 15840
- Han J, 2014, Exp Ther Med, 8, 1330, 10.3892/etm.2014.1918 · DOI
- 10.2119/molmed.2009.00059 · DOI
- 10.1038/gt.2013.88 · DOI
- 10.1158/1078-0432.CCR-12-1568 · DOI
- 10.1038/cgt.2014.68 · DOI
- 10.1002/stem.533 · DOI · Paper page
- 10.1038/cgt.2012.46 · DOI
- 10.1038/cgt.2010.68 · DOI
- 10.1136/thoraxjnl-2013-204110 · DOI
- 10.1038/cddis.2013.19 · DOI
- 10.1016/j.biomaterials.2013.12.037 · DOI
- 10.1002/stem.1355 · DOI
- 10.1016/j.canlet.2009.08.028 · DOI · Paper page
- 10.1097/SLA.0b013e3181bd62d0 · DOI · Paper page
- 10.1097/SLA.0b013e3182368c4f · DOI · Paper page
- 10.1186/s12885-015-1241-x · DOI · Paper page
- 10.1097/SLA.0b013e3181fcb5d8 · DOI
- Karjoo Z, 2016, Adv Drug Deliv Rev
- Jung JH, 2015, Am J Cancer Res, 5, 2686
- 10.1038/cgt.2012.35 · DOI
- 10.1016/j.scr.2011.11.006 · DOI
- 10.1007/s00432-011-1104-z · DOI
- 10.2967/jnumed.114.146662 · DOI · Paper page
- 10.1089/hum.2012.104 · DOI
- 10.1002/stem.665 · DOI · Paper page
- 10.1038/mt.2011.93 · DOI
- 10.1038/sj.cdd.4401187 · DOI · Paper page
- 10.1158/0008-5472.CAN-03-3516 · DOI
- 10.4161/15384047.2014.972183 · DOI
- Sun X-Y, 2011, Anticancer Res, 31, 3705
- Amly W, 2016, Expert Opin Drug Deliv
- 10.1208/s12248-014-9675-7 · DOI
- 10.2174/1566523023347733 · DOI
- 10.1002/jgm.2684 · DOI
- Moolten FL, 1986, Cancer Res, 46, 5276
- 10.1038/sj.mt.6300155 · DOI · Paper page
- 10.1371/journal.pone.0128922 · DOI
- 10.1039/C5BM00077G · DOI
- 10.1016/S0969-8051(99)00105-5 · DOI
- 10.1016/j.nucmedbio.2006.12.009 · doi:10.1016/j.nucmedbio.2006.12.009
- 10.2967/jnumed.106.036830 · DOI
- 10.1016/j.ejca.2011.04.033 · DOI
- 10.3340/jkns.2015.57.5.323 · DOI
- 10.1155/2013/151679 · DOI · Paper page
- 10.1016/j.ijrobp.2008.06.1953 · DOI
- de Araujo Farias V, 2015, Oncotarget, 6, 31164, 10.18632/oncotarget.5216 · DOI
- Ho IA, 2013, Histol Histopathol, 28, 1427
- 10.1038/cdd.2010.154 · DOI
- 10.1016/j.bbrc.2007.03.049 · DOI · Paper page
- 10.1111/cpr.12042 · DOI
- 10.1634/stemcells.2005-0191 · DOI · Paper page
- 10.1186/1757-2215-3-12 · DOI
- 10.1182/blood-2010-10-311464 · DOI · Paper page
- 10.1016/j.biomaterials.2010.03.006 · DOI
- 10.1007/978-1-60761-999-4_35 · DOI · Paper page
- 10.1096/fj.10-178384 · DOI
- 10.1161/CIRCULATIONAHA.108.793208 · DOI · Paper page
- 10.1155/2014/292376 · DOI · Paper page
- 10.1046/j.1365-2265.2002.01640.x · DOI · Paper page
- 10.2174/156800910791054194 · DOI
- 10.1089/hum.2010.158 · DOI
- 10.1089/hum.2011.041 · DOI
- 10.2967/jnumed.112.115493 · DOI
- 10.1055/s-0029-1220744 · DOI
- 10.1038/cgt.2010.4 · DOI
- 10.1038/sj.cgt.7700827 · DOI
- 10.1177/1535370213506802 · DOI
- 10.1186/s13039-015-0197-5 · DOI
- 10.1371/journal.pone.0046425 · DOI
Cited by
Baldari, S., Di Rocco, G., Piccoli, M., Pozzobon, M., Muraca, M., & Toietta, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102087 · Cited by 279
Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1078-8 · Cited by 122
Slama, Y., Ah-Pine, F., Khettab, M., Arcambal, A., Begue, M., Dutheil, F., & Gasque, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713511 · Cited by 57
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Stamatopoulos, A., Stamatopoulos, T., Gamie, Z., Kenanidis, E., Ribeiro, R. D. C., Rankin, K. S., Gerrand, C., Dalgarno, K., & Tsiridis, E. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100231 · Cited by 37
“cytosine deaminase (CD) combined with 5-fluorocytosine (5-FC) and carboxylesterase with the prodrug CPT-11 (irinotecan) for the treatment of colon cancer, osteosarcoma [132] or glioblastoma and brain stem glioma, respectively [133].”
BackgroundThe role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
Metadata
- Authors
- Hagenhoff, A., Bruns, C. J., Zhao, Y., von Lüttichau, I., Niess, H., Spitzweg, C., & Nelson, P. J.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2016-06-13
- Volume
- 16
- Issue
- 9
- Pages
- 1079-1092
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2414142847
- Cited by
- 47
- References
- 26
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Deutsche Forschungsgemeinschaft (NE 648/5-2, SFB824 project C 08, SP 581/6-2)
- Wilhelm-Sander-Stiftung (2014.129.1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Harnessing mesenchymal stem cell homing as an anticancer therapy. https://app.cochat.ai/papers/10.1080/14712598.2016.1196179
- The paper
- Hagenhoff, A., Bruns, C. J., Zhao, Y., von Lüttichau, I., Niess, H., Spitzweg, C., & Nelson, P. J. (2016). Harnessing mesenchymal stem cell homing as an anticancer therapy. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2016.1196179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.